ReCode Therapeutics
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $50M
Overview
A genetic medicine company pioneering selective organ targeting (SORT) LNP delivery for respiratory and metabolic diseases.
RespiratoryMetabolicGenetics & Genomics
Technology Platform
A proprietary Selective Organ Targeting (SORT) lipid nanoparticle platform that enables tissue-specific delivery of genetic medicines, including mRNA and gene editing payloads.
Funding History
1Total raised:$50M
Series B$50M
Opportunities
Platform potential to enable a new class of genetic medicines for diseases in the lungs and other organs where delivery has been a major barrier.
Risk Factors
Clinical validation risk for its novel delivery platform and intense competition in the mRNA and gene therapy spaces.
Competitive Landscape
Competes with other genetic medicine delivery specialists and large mRNA companies, but is differentiated by its focus on tissue-specific LNP engineering for non-liver targets.